SureTrader Advertisement PRTC
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board:
Last Post: 5/28/2016 10:51:28 PM - Followers: 163 - Board type: Free - Posts Today: 5

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CVM News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 05/20/2016 01:50:28 PM
CVM News: Current Report Filing (8-k) 05/19/2016 04:22:00 PM
CVM News: CEL-SCI Announces $5 Million Registered Direct Offering 05/18/2016 09:00:00 AM
CVM News: CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results 05/10/2016 04:40:00 PM
CVM News: Quarterly Report (10-q) 05/10/2016 04:33:12 PM
PostSubject
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#7359  Sticky Note News! Ergomed Increases Its Co-Development Contribution up to $12,000,000 trickledownfacists 10/05/15 08:40:16 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#8248   Right on. Misunderstood. trickledownfacists 05/28/16 10:51:28 PM
#8247   Not what I said - or what I drkazmd65 05/28/16 08:42:20 PM
#8246   Even if it's another record month you would trickledownfacists 05/28/16 08:08:38 PM
#8245   I do not expect any monthly specific numbers drkazmd65 05/28/16 06:48:34 PM
#8244   I don't expect another month of enrollment in trickledownfacists 05/28/16 02:40:33 PM
#8243   Re: Navy study. Nothing new and no NIH Foxwoods Man 05/26/16 08:50:59 AM
#8242   Agreed. I would love to see any news trickledownfacists 05/25/16 02:10:02 PM
#8241   Well, big pharma could step up and foot Turney 05/25/16 01:57:47 PM
#8240   While I like the idea of LEAPS,.... and drkazmd65 05/25/16 12:45:17 PM
#8239   One would hope so... trickledownfacists 05/24/16 08:24:18 PM
#8238   Might LEAPS work on ZIKA? Turney 05/24/16 06:38:52 PM
#8237   Yes. Thanks D. Yet, it depressed ducruacuteo11 05/24/16 11:54:41 AM
#8236   Thanks. ..makes perfect sense Foxwoods Man 05/24/16 11:24:44 AM
#8235   Read the study design and what they are drkazmd65 05/24/16 11:20:05 AM
#8234   This first part is only partially true FM: drkazmd65 05/24/16 11:15:54 AM
#8233   With no update results allowed by the FDA steve2150 05/24/16 11:11:23 AM
#8232   Yes there are rules from the FDA that Turney 05/24/16 10:15:49 AM
#8231   Sabby healthcare master fund now owns 5% of CVM. trickledownfacists 05/24/16 09:10:55 AM
#8230   There is nothing preventing preliminary results from being Foxwoods Man 05/24/16 06:19:53 AM
#8229   The increase in enrollment after the replacement of Turney 05/23/16 10:43:33 PM
#8228   Thanks for the vote of confidence, FM. ducruacuteo11 05/23/16 06:16:49 PM
#8227   Two things worry me about this company: Foxwoods Man 05/23/16 04:39:43 PM
#8226   I wouldn't worry about those warrents CVM stock Turney 05/23/16 03:04:49 PM
#8225   I thought it would be worse. Most ducruacuteo11 05/23/16 02:28:20 PM
#8224   What I meant was the market reacted as Turney 05/21/16 02:45:22 PM
#8223   I guess if a 10% drop in the Foxwoods Man 05/21/16 07:33:52 AM
#8222   The market is tellin' us what it thinks Turney 05/20/16 02:33:37 PM
#8221   CVM News: Current Report Filing (8-k) 05/19/2016 04:22:00 PM mick 05/20/16 01:49:01 PM
#8220   Cel-Sci Corp. ($0.00 (CVM) mick 05/20/16 01:48:53 PM
#8219   Article re CVM yesterday in Smallcapnetworkdotcom MsMom1 05/19/16 02:57:03 PM
#8218   When and if approved what guess at $ share steve2150 05/19/16 07:03:03 AM
#8217   Interesting to think about.... trickledownfacists 05/18/16 06:38:28 PM
#8216   In the company's history has there ever been georgebailey 05/18/16 04:08:34 PM
#8215   Iroquois Capital...? trickledownfacists 05/18/16 11:06:29 AM
#8214   Agreed,... it'll be interesting to see whom it drkazmd65 05/18/16 10:48:01 AM
#8213   Yup, expected. trickledownfacists 05/18/16 10:41:16 AM
#8212   Even though you know something sometimes you still pijoe 05/18/16 10:38:55 AM
#8211   It will be interesting to see who is sab63090 05/18/16 10:29:35 AM
#8210   I am guessing that none of 'us' are drkazmd65 05/18/16 09:47:08 AM
#8209   5 million.. wish I had that!!! Hurry up pijoe 05/18/16 09:21:05 AM
#8208   The last date that was mentioned was "sometime Foxwoods Man 05/16/16 11:12:58 AM
#8207   Does anyone know the date they are suppose ed2000 05/16/16 10:48:04 AM
#8206   60 minutes story steve2150 05/16/16 07:02:19 AM
#8205   I always believed polio got a bad wrap. Hhrmmpf pijoe 05/16/16 06:24:46 AM
#8204   good story about brain cancer on 60 minutes. Turney 05/15/16 07:34:57 PM
#8203   Exciting times as we get closer to the pijoe 05/15/16 01:56:35 PM
#8202   I may be wrong here but I don't Foxwoods Man 05/13/16 08:16:51 PM
#8201   I agree, very good sign. trickledownfacists 05/13/16 11:23:22 AM
#8200   that is good news----the hospital and this doctor georgebailey 05/13/16 08:37:53 AM
#8199   For the market they are listed on there trickledownfacists 05/12/16 07:43:11 PM
PostSubject